JPWO2020072601A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020072601A5 JPWO2020072601A5 JP2021518610A JP2021518610A JPWO2020072601A5 JP WO2020072601 A5 JPWO2020072601 A5 JP WO2020072601A5 JP 2021518610 A JP2021518610 A JP 2021518610A JP 2021518610 A JP2021518610 A JP 2021518610A JP WO2020072601 A5 JPWO2020072601 A5 JP WO2020072601A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutical composition
- poloxamer
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 143
- 238000000034 method Methods 0.000 claims description 70
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 53
- 229920001983 poloxamer Polymers 0.000 claims description 46
- 229960000502 poloxamer Drugs 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 19
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 17
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 14
- 229960000604 valproic acid Drugs 0.000 claims description 14
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 8
- 150000001299 aldehydes Chemical class 0.000 claims description 7
- 229920001992 poloxamer 407 Polymers 0.000 claims description 7
- 229940044476 poloxamer 407 Drugs 0.000 claims description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 6
- 206010011891 Deafness neurosensory Diseases 0.000 claims description 5
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims description 5
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims description 5
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims description 5
- 229940084026 sodium valproate Drugs 0.000 claims description 5
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 5
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000012535 impurity Substances 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229920000428 triblock copolymer Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 3
- 229940125703 otic agent Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739933P | 2018-10-02 | 2018-10-02 | |
| US62/739,933 | 2018-10-02 | ||
| PCT/US2019/054235 WO2020072601A1 (en) | 2018-10-02 | 2019-10-02 | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022504265A JP2022504265A (ja) | 2022-01-13 |
| JPWO2020072601A5 true JPWO2020072601A5 (enExample) | 2022-10-07 |
Family
ID=68296763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518610A Withdrawn JP2022504265A (ja) | 2018-10-02 | 2019-10-02 | 耳治療薬に関する医薬組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220192984A1 (enExample) |
| EP (1) | EP3860562A1 (enExample) |
| JP (1) | JP2022504265A (enExample) |
| KR (1) | KR20210084484A (enExample) |
| CN (1) | CN113164381A (enExample) |
| BR (1) | BR112021006092A2 (enExample) |
| CA (1) | CA3114113A1 (enExample) |
| MX (1) | MX2021003773A (enExample) |
| TW (1) | TW202034900A (enExample) |
| WO (2) | WO2020072602A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| AU2019321641A1 (en) * | 2018-08-17 | 2021-04-15 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating Jag-1 |
| CA3136424A1 (en) * | 2019-04-08 | 2020-10-15 | Frequency Therapeutics, Inc. | Combination of chir99021 and valproic acid for treating hearing loss |
| CN114085803B (zh) * | 2020-08-24 | 2024-04-26 | 北京大学 | 建立具有再生特性的类器官培养体系 |
| JP2023545177A (ja) * | 2020-10-14 | 2023-10-26 | イアー サイエンス インスティテュート オーストラリア | 内耳有毛細胞を生成する方法 |
| US20240180882A1 (en) * | 2021-03-08 | 2024-06-06 | The Regents Of The University Of California | Compounds for protection of noise-induced hearing-loss |
| AU2023390101A1 (en) * | 2022-12-07 | 2025-06-19 | Freedom Biosciences, Inc. | Treatment or prevention of depressive disorders through combination therapy |
| CN120053473B (zh) * | 2025-04-25 | 2025-07-18 | 山东大学 | 赖氨酸甲基转移酶dot1l抑制剂在制备治疗肝脏缺血再灌注损伤药物中的应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US447475A (en) | 1891-03-03 | pomerof | ||
| US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US5346703A (en) | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| EP1109563A4 (en) | 1998-08-04 | 2009-07-22 | Madash Llp | HEAT-SENSITIVE HYDROGELS WITH MODIFIED TERMINATION |
| US6761824B2 (en) | 2000-08-17 | 2004-07-13 | Reeve Lorraine E | Process for the fractionation of polymers |
| WO2009009737A1 (en) * | 2007-07-12 | 2009-01-15 | Neurosci, Inc. | Sustained release formulation of active pharmaceuticals in a lipid based sustained release |
| CN101990433B (zh) | 2008-02-07 | 2014-11-05 | 马萨诸塞眼科耳科诊所 | 提高Atoh1表达的化合物 |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
| WO2013178821A1 (en) | 2012-06-01 | 2013-12-05 | Leibniz-Institut für Altersforschung - Fritz-Lipmann-Institut e.V. (FLI) | Inhibitors of the notch signalling pathway and secretion for use in medicine |
| CA2883896C (en) | 2012-09-07 | 2023-03-07 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| WO2014047397A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
| TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2014047370A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| US9187434B2 (en) | 2012-09-21 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinones compounds |
| JP2015531792A (ja) | 2012-09-21 | 2015-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | １，４−ベンゾジアゼピノン化合物のプロドラッグ |
| US9249157B2 (en) | 2012-09-21 | 2016-02-02 | Bristol-Myers Squibb Company | Tricyclic heterocycle compounds |
| WO2014047374A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
| EP2897954B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
| US9572815B2 (en) | 2013-03-15 | 2017-02-21 | St. Jude Children's Research Hospital | Methods and compositions of p27KIP1 transcriptional modulators |
| CN103169649A (zh) * | 2013-04-11 | 2013-06-26 | 中国人民解放军总医院 | 温度和离子双重敏感型原位凝胶鼻腔给药系统 |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| KR102493376B1 (ko) * | 2014-09-03 | 2023-01-27 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법 |
| WO2016056999A1 (en) | 2014-10-08 | 2016-04-14 | Agency For Science, Technology And Research | Methods of differentiating stem cells into liver cell lineages |
| JO3491B1 (ar) | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| JP6900378B2 (ja) | 2015-12-22 | 2021-07-07 | ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ | ポリエーテルブロックコポリマーの精製方法 |
| US10213511B2 (en) * | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) * | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| CN109311878B (zh) | 2016-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 作为γ-分泌酶调节剂的三唑并吡啶类化合物 |
| EP3481829B1 (en) | 2016-07-08 | 2021-04-07 | H. Hoffnabb-La Roche Ag | Fused pyrimidine derivatives |
| EP3484884B1 (en) | 2016-07-14 | 2021-01-27 | Hoffmann-La Roche AG | Fused pyrimidine derivatives |
| AR109829A1 (es) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| JP6956175B2 (ja) | 2016-10-04 | 2021-11-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二環式ヘテロアリール誘導体 |
| WO2018087018A1 (en) | 2016-11-08 | 2018-05-17 | F. Hoffmann-La Roche Ag | Phenoxytriazoles |
| EP3554502A4 (en) | 2016-12-16 | 2021-01-06 | Pipeline Therapeutics, Inc. | METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY |
| EP3558950B1 (en) | 2016-12-20 | 2023-05-10 | Oligomerix, Inc. | Novel quinazolinones that inhibit the formation of tau oligomers and their method of use |
| WO2018118782A2 (en) | 2016-12-20 | 2018-06-28 | Oligomerix, Inc. | Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use |
| US10383881B2 (en) | 2016-12-30 | 2019-08-20 | Frequency Therapeutics, Inc. | 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same |
| CN110392686A (zh) | 2016-12-30 | 2019-10-29 | 频率治疗公司 | 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法 |
| JP2020511486A (ja) | 2017-03-24 | 2020-04-16 | ノバルティス アーゲー | イソオキサゾールカルボキサミド化合物及びその使用 |
-
2019
- 2019-10-02 US US17/282,069 patent/US20220192984A1/en not_active Abandoned
- 2019-10-02 MX MX2021003773A patent/MX2021003773A/es unknown
- 2019-10-02 CA CA3114113A patent/CA3114113A1/en active Pending
- 2019-10-02 EP EP19791035.9A patent/EP3860562A1/en not_active Withdrawn
- 2019-10-02 WO PCT/US2019/054236 patent/WO2020072602A1/en not_active Ceased
- 2019-10-02 WO PCT/US2019/054235 patent/WO2020072601A1/en not_active Ceased
- 2019-10-02 KR KR1020217013189A patent/KR20210084484A/ko not_active Withdrawn
- 2019-10-02 TW TW108135698A patent/TW202034900A/zh unknown
- 2019-10-02 JP JP2021518610A patent/JP2022504265A/ja not_active Withdrawn
- 2019-10-02 BR BR112021006092-8A patent/BR112021006092A2/pt not_active Application Discontinuation
- 2019-10-02 CN CN201980079535.3A patent/CN113164381A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6870867B2 (ja) | メロキシカムを含有する医薬組成物 | |
| CN100563655C (zh) | 治疗牛和猪感染的组合物及其用途 | |
| KR102233537B1 (ko) | 항균성 폴리아미드 조성물 및 유방염 치료 | |
| CN1195504C (zh) | 含非甾族消炎止痛剂的外用药物制剂 | |
| JPWO2020072601A5 (enExample) | ||
| JP2018528962A (ja) | 熱感受性ヒドロゲルコラゲナーゼ製剤 | |
| EP3478300A1 (en) | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells | |
| CN101897687B (zh) | 丙戊酸钠治疗肝脏炎症相关疾病的新用途 | |
| US6521243B2 (en) | Ionic chitosan -iodine complexes: antiseptic hydrogels and wound healing promoters | |
| JP3140409B2 (ja) | 安定なプロスタグランジンｅ１−含有注射剤組成物 | |
| CN105287607A (zh) | 兽用复方盐酸多西环素氟苯尼考缓释微球混悬注射液 | |
| KR101810156B1 (ko) | 폴리에틸렌 글리콜 및 플라보노이드 나노복합체를 유효성분으로 함유하는 안구 건조증 예방 또는 치료용 조성물 | |
| Pan | Ultrasound guided intralesional bleomycin therapy for cystic lymphangioma in childhood | |
| WO2025040177A1 (zh) | 一种适用于耳鼓给药的地塞米松磷酸钠冻干组合物及其制备方法 | |
| JP2007517847A (ja) | セルロース誘導体で架橋された柑橘類複合糖質のゲル組成物 | |
| JP2007506660A (ja) | フルピルチンの注射用医薬形 | |
| CN113811309B (zh) | 用于治疗病毒感染的聚合物制剂及制备方法和用途 | |
| CN115998840A (zh) | 含多肽类物质的组合物及其制备方法、制剂和应用 | |
| RU2423130C2 (ru) | Композиция, содержащая эпопростенол, и способ ее получения | |
| CN115887354A (zh) | 一种消化道粘膜损伤快速修复新材料及制备方法 | |
| CN103845463B (zh) | 治疗马骨关节炎性肿胀的中药透皮剂及其制备方法 | |
| WO2021157619A1 (ja) | 膵液瘻の予防または治療剤 | |
| CN112535708A (zh) | 一种含妥布霉素和中药提取物的凝胶组合物及其制备方法 | |
| CN118161478B (zh) | 肥大细胞抑制剂在制备防治猪繁殖与呼吸综合征早期感染药物中的应用 | |
| CN114025746A (zh) | 抗血栓形成剂的可注射聚合物纳米颗粒组合物及其方法 |